Dr Reddy's Laboratories launches Docetaxel injection in US

Dr Reddy's Laboratories has launched Docetaxel injection USP 20 mg/mL and 80 mg/4 mL, a generic version of Taxotere (docetaxel injection) in the US market.

Dr Reddy's Abbreviated New Drug Application (ANDA) is approved by the United States Food & Drug Administration (USFDA), DRL said in a statement on Monday.

Taxotere (docetaxel) is a cancer medication that interferes with the growth and spread of cancer cells in the body.

Its brand and generic versions have US sales of approximately USD 218 million MAT for the most recent 12 months ending in September, the drug maker said quoting IMS Health data.

Dr Reddy's Docetaxel injection USP 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does not require a prior dilution with a diluent and is ready to add to the intravenous infusion solution, it added.